Theflyonthewall.com is Wall Street's specialist in breaking equity news. Veteran traders build a proprietary feed of news that's faster and more relevant than any other source. Try us for free and discover for yourself.
Theflyonthewall.com is Wall Street's specialist in breaking equity news. Veteran traders build a proprietary feed of news that's faster and more relevant than any other source. Try us for free and discover for yourself.
China Medical Technologies, Inc. (ADR) (NASDAQ: CMED) decreased $2.56 or 16.90% to $15.15 after it reported a second quarter net loss of RMB 47.09 million against a profit of RMB 117.73 million from the same quarter last year. Net earnings were RMB 17.67 million as compared to RMB 102.09 million. CMED also provided its third quarter revenue guidance. Yesterday, CMED closed at $15.15.
NetEase.com, Inc. (ADR) (NASDAQ: NTES) plunged 8.36% to $37.35 after it reported a third quarter net profit of RMB 393.8 million against 313.3 million. Total revenues for 3Q2009 were RMB 879.4 million as compared to RMB 806.6 million from the same quarter last year. The 52 week trading range for NTES is $15.00 -$48.50.
Microvision, Inc. (NASDAQ: MVIS) plunged 16% to $3.45 in the pre-market. Yesterday, Microvision, Inc. announced that it plans to offer common stock in an underwritten public offering. In 2009, shares of MVIS gained over 144%. The 52 week trading range for MVIS is $0.77 - $5.75.
Hot Topic, Inc. (NASDAQ: HOTT) plummeted 11.90% to $5.87 in the pre-market trading. So far this year, HOTT is down 28%. Yesterday HOTT announced that for 4Q2009, it expects earnings to be below analysts’ expectation.
Affymax, Inc. (NASDAQ: AFFY) decreased 4.02% to $19.89 after Affymax announced that it plans to offer shares of its common stock in an underwritten public offering.
Comverge, Inc. (NASDAQ: COMV) declined 4.48% to $10.87 in the pre-market session. So far this year, COMV is up over 119%.
Theflyonthewall.com is Wall Street's specialist in breaking equity news. Veteran traders build a proprietary feed of news that's faster and more relevant than any other source. Try us for free and discover for yourself.
Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.Affymax, Inc. (Nasdaq: AFFY), today announced that it intends to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering.Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced new pre-clinical data from its ALN-VSP program presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International conference being held November 15 - 19, 2009 in Boston, Mass.BSD Medical Corporation (NASDAQ: BSDM) (www.bsdmedical.com) today provided an update on the U.S. Food and Drug Administration’s (FDA) review of the Company's Humanitarian Device Exemption (HDE) marketing submission for the Company’s BSD-2000 Hyperthermia System.Clinical Data, Inc. (NASDAQ: CLDA) today announced that it has enrolled the first patient in its initial Phase III trial of Stedivaze™, a potential best-in-class vasodilator for use in cardiac stress testing.Delcath Systems, Inc. (Nasdaq: DCTH) announced today the closing of its public offering of 9,775,000 shares of common stock priced to the public at $3.60 per share.CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company, today announced plans to initiate an open-label, multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a second-line treatment in patients with advanced gastric (stomach) cancer.Depomed, Inc. (NASDAQ:DEPO) announced today that William Callahan has been promoted to vice president, Operations. Mr. Callahan joined Depomed in 2002 and most recently held the position of senior director, Operations.Exelixis, Inc. (Nasdaq:EXEL) today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with the EGFR inhibitor erlotinib in patients with advanced solid tumors.PPD, Inc. (NASDAQ:PPDI) today announced it has signed an agreement to acquire BioDuro LLC, a drug discovery outsourcing company that provides a broad range of integrated services to biopharmaceutical companies. The acquisition will expand PPD’s drug development capabilities in China.Pfizer Inc (NYSE:PFE) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee voted 10 to 1 that the data presented support the safety and effectiveness of its 13-valent pneumococcal conjugate candidate vaccine, Prevnar 13™ (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for the prevention of invasive pneumococcal disease in infants and young children. Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), a specialty pharmaceutical company, today announced the pricing of a public offering of 5,500,000 shares of its common stock.Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today reported data from two nonclinical studies of voreloxin at the AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference, which is being held in Boston, MA from November 15-19, 2009.Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today presented new data on the mechanism of action of elesclomol, a first-in-class oxidative stress inducer, at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics in Boston, Mass.Tongjitang Chinese Medicines Company (NYSE: TCM) (“Tongjitang” or the “Company”), a leading specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China, today announced its financial results for the quarter ended September 30, 2009 and the repurchase of ordinary shares in a private transaction.YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, announced that results from a study evaluating nimotuzumab were presented today in a poster at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference in Boston, Massachusetts.
Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.
EpiCept Corporation (Nasdaq:EPCT) announced a Nasdaq Hearings Panel has granted the Company’s request for continued listing on The Nasdaq Stock Market.
GenVec, Inc. (Nasdaq:GNVC) announced Paul H. Fischer, Ph.D., President and CEO, will present a company overview highlighting recent developments at the Merriman Curhan Ford's 6th Annual Investor Summit on Tuesday, November 10, 2009 at 9:20 am EST at Sofitel Hotel in New York, NY.
Enzon Pharmaceuticals, Inc. (Nasdaq:ENZN) announced its third quarter 2009 financial results. For the three months ended September 30, 2009, Enzon reported a net income of $0.1 million or break-even on a diluted per-share basis, as compared to a net loss of $2.0 million or $0.05 on a diluted per-share basis for the third quarter of 2008.
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) announced Jonathan Lewis, MD, PhD, Chief Executive Officer, will present at the 6th Annual Merriman, Curhan, Ford Investor Summit on Tuesday, November 10, 2009 at 12:20 pm ET at the Soffitel Hotel in New York, NY. Dr. Lewis will provide an overview of the Company and its clinical development programs.
Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) reported results for the quarter ended September 30, 2009.
Aetna (NYSE:AET) is providing free electronic roster billing for pharmacies and other non-traditional providers to use when submitting claims for the administration of the H1N1 flu vaccine.
Stem Cell Therapy International Inc. (OTC:SCII) and its soon to be subsidiary, Histostem Ltd. of South Korea ("Histostem"), announced they have entered into a definitive agreement for up to a $5 million investment commitment with Socius Life Science Capital Group, LLC.The Company's plan is to have funds available no later than December 31, 2009 and use the proceeds for various growth initiatives, including the launch of its stem cell based facial cream, the initiation of clinical trials, maintaining and advancement of current GMP facility as well as ongoing working capital and general corporate purposes.
NanoLogix, Inc. (OTC:NNLX), announces the company has recently filed BNP™ (BioNanoPore) national patent applications in China, Japan, India, Brazil, Russia and the EU.
Sinovac Biotech Ltd. (NYSE:SVA), a leading developer and provider of vaccines in China, announced it will voluntarily transfer its stock exchange listing from the NYSE Amex to the NASDAQ Global Market.
Solos Endoscopy, Inc. (OTC:SNDY) is pleased to announce the Company has received purchase orders for its MammoView(TM) line of surgical endoscopy instruments from various hospitals under Catholic Health Initiatives, Littleton, CO.
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,612,199 (the ‘199 patent) entitled “Polymorphic Forms Alpha, Beta, and Gamma of Rifaximin”.
Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) announced Robert Perez, EVP and COO, will present on Wednesday, November 18, 2009 at 1:45 p.m. Eastern Time at the Lazard Capital Markets 6th Annual Healthcare Conference at the St Regis Hotel in New York City.
Merck & Co., Inc. (NYSE:MRK) and Schering-Plough Corporation (NYSE:SGP) announced they will complete their merger shortly after 4:00PM ET.
Advanced Cell Technology, Inc. (OTC:CTC) announced its Chief Executive Officer, William Caldwell, IV, presented at the BIO Europe Conference being held in Vienna, Austria.
Catalyst Health Solutions, Inc. (NASDAQ:CHSI), a pharmacy benefit management company, announced its financial results for the third quarter ended September 30, 2009.
Optigenex Inc. (OTC:OPGX), has unveiled a new information web page www.optigenex.com designed to connect with prospective corporate customers and partners in the wellness and personal care industries.
Walgreens (NYSE:WAG) executive vice president and chief financial officer Wade Miquelon will present during the Credit Suisse Annual Healthcare Conference in Phoenix on Thursday, Nov. 12, 2009 at approximately 10 a.m. MST (noon EST).
BioMimetic Therapeutics, Inc. (NASDAQ:BMTI) announced the Company plans to release its financial results for the three and nine months ended September 30, 2009, on Thursday, November 5, 2009 after the close of the market.
BIOLASE Technology, Inc. (NASDAQ:BLTI), the world's leading dental laser company, announced the launch of the Diolase 10™ Diode Laser for therapeutic applications, including temporary pain relief.
Aethlon Medical, Inc. (OTC:AEMD) announced it has initiated a collaborative biomarker discovery program with the Center for the Study of Traumatic Encephalopathy (CSTE) at Boston University School of Medicine and the Sports Legacy Institute (SLI).
ULURU Inc. (NYSE:ULU) announced it has scheduled a conference call to discuss the third quarter ended September 30, 2009 financial results and provide a general business update on Tuesday, November 17, 2009 at 9:00 a.m. Eastern Time.
CNS Response, Inc. (OTC:CNSO) reported the results of a landmark study presented by Charles DeBattista, D.M.H, M.D., at the U.S. Psychiatric and Mental Health Congress.
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,612,199 (the ‘199 patent) entitled “Polymorphic Forms Alpha, Beta, and Gamma of Rifaximin”.
Viriathus Research LLC, an independent research firm, issued an Update Report for Viralytics Limited (OTC: VRACY), a biotechnology company which is developing therapies and drugs for the treatment of cancer in Australia.
Affymax, Inc. (Nasdaq:AFFY) announced the appointment of Hollings C. Renton to the position of chairman of the company’s board of directors effective December 1, 2009.
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) announced Jonathan Lewis, MD, PhD, Chief Executive Officer, will present at the 6th Annual Merriman, Curhan, Ford Inventor Summit on Tuesday, November 10, 2009 at 12:20 pm ET at the Soffitel Hotel in New York, NY. Dr. Lewis will provide an overview of the Company and its clinical development programs.
Walgreens (NYSE:WAG), the nation’s largest drugstore chain and industry leader with more than 17,000 certified or licensed immunizers, will begin offering H1N1 injectable vaccines at 18 pharmacies throughout Salt Lake County Thursday.
Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.
Lannett Company, Inc. (NYSE:LCI), a manufacturer of generic pharmaceuticals, announced the company will release its fiscal 2010 first-quarter financial results on Monday, November 9, 2009.
Catalyst Health Solutions, Inc. (NASDAQ:CHSI), a pharmacy benefit management company, announced its financial results for the third quarter ended September 30, 2009.
SuperGen, Inc. (Nasdaq:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced Mohammad Azab, M.D., Chief Medical Officer, will present at the Merriman Curhan Ford 6th Annual Investor Summit on Tuesday November 10, 2009 in New York.
Unigene Laboratories, Inc. (OTC:UGNE) will release financial results for the quarter ended September 30, 2009, after the market closes on Monday, November 9, 2009.
Emisphere Technologies, Inc. (OTC:EMIS) announced management will host a conference call to discuss the Company’s financial and operational results for the third quarter ended September 30, 2009 on Monday, November 9, 2009 at 10:00 AM EST.
BioClinica™, Inc. (NASDAQ:BIOC), a global provider of clinical trial services, announced its financial results for the quarter and nine months ended September 30, 2009.
Universal Detection Technology (OTC:UNDT), a developer of early-warning monitoring technologies to protect people from bioterrorism and other infectious health threats, announced it is expanding its product catalogue to include a consumer-ready kit for the detection of black mold.
Emdeon® (NYSE:EM), a leading provider of healthcare revenue and payment cycle management solutions, announced its eRx Network® will provide real-time electronic billing solutions to retail pharmacies for the nation's top 25 medical payers in light of the dramatic increase in H1N1 vaccinations being administered by pharmacies.
Phase Forward (NASDAQ:PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced its senior vice president and chief financial officer, Chris Menard, and senior vice president of integration and product strategy, Martin Young, will present at the 18th Annual Credit Suisse Healthcare Conference at the Arizona Biltmore Hotel in Phoenix, Arizona.
Medidata Solutions (NASDAQ:MDSO), a leading global provider of hosted clinical development solutions, announced a multi-year contract extension with Shire plc (NASDAQ:SHPGY) for use of Medidata Grants Manager™ and CRO Contractor™ benchmarking and analysis tools for investigator site and contract research organization (CRO) trial budget planning and forecasting.
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), reported financial results for the quarter ended September 30, 2009, and provided details on further developments.
AcuMedSpa Holdings, Inc. (OTC:AMSZ) is pleased to announce that it has reached an agreement with Santa Barbara Medical Innovations (SBMI) to become a preferred provider of the popular Zerona protocol which is a proven, non-invasive cold laser solution for unwanted body fat as well as for body slimming and contouring. Zerona has been featured in dozens of magazines and on TV shows such as "Rachael Ray," "Extra" and "The Doctors."
Advanced Life Sciences Holdings, Inc. (OTC:ADLS), announced it will host a conference call and webcast discussing the Company's 2009 third quarter results on Tuesday, November 10, 2009 at 10:00 a.m. (EST).
InterMune, Inc. (Nasdaq:ITMN) announced it has submitted an electronic New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF).
Javelin Pharmaceuticals, Inc. (NYSE:JAV) announced its CEO, Martin J. Driscoll, and Stephen J. Tulipano, CFO, will host a conference call to discuss the Company's quarterly results for the period ending September 30, 2009.
Lannett Company, Inc. (NYSE:LCI), a manufacturer of generic pharmaceuticals, announced the company will release its fiscal 2010 first-quarter financial results on Monday, November 9, 2009.
Unilife Medical Solutions Limited (OTC:UNIFF) (Unilife Australia) entered into a Merger Implementation Agreement with Unilife Corporation (Unilife USA) to facilitate the proposed redomiciliation of the Unilife group in the United States of America (Proposed Transaction).
Aeolus Pharmaceuticals, Inc. (OTC:AOLS) reported researchers from National Jewish Health and McGill University have completed a series of preliminary studies demonstrating that AEOL 10150 protects lungs from chlorine gas exposure in mice.
Pro-Pharmaceuticals, Inc. (OTC:PRWP) announced it has closed a $310,000 tranche of a private placement of up to $6.0 million with 10X Fund, L.P., which is purchasing unregistered Series B convertible preferred stock and warrants.
Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Global Research & Development Center, Inc., announced data from a Phase 2 clinical trial of Hematide™ showing that Hematide increased hemoglobin and reduced or eliminated the need for blood transfusion in most patients with erythropoietin-induced pure red cell aplasia (PRCA).
Alkermes, Inc. (NASDAQ:ALKS) announced its corporate presentation will be webcast live by Credit Suisse on Wednesday, November 11, 2009, at 5:00 p.m MT (7:00 p.m. ET) from the Arizona Biltmore Hotel in Phoenix, Arizona.
Flamel Technologies (Nasdaq:FLML) expects to release its financial results for the third quarter of 2009 the morning of November 16th, before the market opening.
Neurogen Corporation (NASDAQ:NRGN), a drug development company, announced it will release its third quarter 2009 financial results on Friday, November 6, 2009 before the opening of the U.S. financial markets.
Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, reported financial and operating results for the quarter ended September 30, 2009.
Genta Incorporated (OTC:GETA) announced the Company will release its third quarter 2009 financial results on Monday, November 16, 2009.
Gilead Sciences, Inc. (Nasdaq:GILD) announced its corporate presentation will be webcast from the 18th Annual Credit Suisse Healthcare Conference in Phoenix.
SurModics, Inc. (Nasdaq:SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, reported financial results for the fourth quarter and fiscal year ended September 30, 2009.
Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of about 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following additional categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete re (...)[More...]
Posted By Optiondragon for Myhappytrading.com- The best social network for traders on the internet! Made BY Awesome Traders for Awesome Traders.[More...]
All News |
Breaking News |
Featured Stories